Maximize in-house retention
Eliminate unnecessary outbound referrals. Equip your team with diagnostic precision to manage suspicious lesions under your own roof.
Bring the only FDA-Cleared AI Skin Cancer Detection to Your Practice
Assess suspicious skin lesions at the point of care with immediate skin cancer risk results through a low monthly subscription designed to fit your practice.
See DermaSensor in Action. Request Your Demo. See how DermaSensor can fit into your clinical workflow.
1 (855) 373-6767
99%
of physicians agreed the device added value to their clinical care;*
81%
Reported increased confidence in evaluating skin lesions.*
52%
Reduction in missed cancer referrals*
*Clinical Evidence Upon Request
FDA-Cleared AI Technology | Non-Invasive | Immediate Results
This product is intended for use by licensed physicians only. Not for general or individual sale.
Featured In Recognized Media Channels
Detect more skin cancers at point of care
Boost practice revenue and patient confidence
Low monthly subscription
Our low monthly subscription model replaces heavy capital expenses with no upfront hardware fees.
1:1 Reimbursement support
Most government and commercial insurance plans provide coverage for DermaSensor services. Your monthly subscription costs can be covered by scanning just a few patients.
Schedule a quick 30-minute demo.
Key Features
-
Non-Invasive Assessment
DermaSensor assesses lesions quickly and accurately without cutting, scraping, or invasive tissue sampling, providing a trustworthy risk assessment tool that remains comfortable for patients.
-
Rapid Results
The device captures five spectral recordings in seconds, then delivers an immediate result of “Monitor” or “Investigate Further” at the point of care.
-
Trusted AI-Powered Technology
Powered by a proprietary, FDA-cleared AI algorithm trained on over 20,000 scans from more than 4,000 lesions, the device analyzes spectral data to provide an objective skin cancer risk result.
-
Clinically Validated
The FDA pivotal study demonstrated a 96% sensitivity for detecting all three major skin cancer types, including melanoma, basal cell carcinoma, and squamous cell carcinoma.
With fast results, simple operation, and clinically validated performance, DermaSensor fits naturally into everyday workflows for evaluating suspicious skin lesions. Contact our team to learn more.
Real results. Real stories.
Hear directly from primary care physicians and specialists who use DermaSensor in clinical practice. Learn how DermaSensor strengthens clinical confidence when assessing the risk of skin cancer and melanoma while improving patient communication.
“I think this is a revolutionary new product that can help us aid in the management of safety and wellness for our patients. In that, we can highlight and see whether any areas, dark areas, could potentially be cancerous.”
Hear directly from primary care physicians and specialists who use DermaSensor in clinical practice. Learn how DermaSensor strengthens clinical confidence when assessing the risk of skin cancer and melanoma while improving patient communication.
We are dedicated to equipping physicians and medical providers with intelligent tools to detect skin cancer earlier and more accurately.
Get the latest insights from DermaSensor straight to your inbox
Subscribe to receive news, events, and documents
80-0009.31
